Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

SARASOTA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that Chief Medical Officer Dr. James Kelly participated in a panel discussion at the 3rd Nasal Formulation & Delivery Summit, which took place April 1-3, 2025, in Boston, MA. The conference brought together industry leaders to discuss the latest innovations in intranasal drug delivery, with a focus on CNS therape ...